Survival, clinical and biological outcomes of HIV-infected children treated by antiretroviral therapy in Africa: Systematic review, 2004-2009;Survie et évolution clinique et biologique des enfants infectés par le VIH traités par les antiretroviraux en Afrique: revue de littérature, 2004-2009

Presse Medicale

Volumn 40, Issue 7-8, 2011, Pages

  Ndondoki, Camille ^a,b   Dabis, François ^a,b   Namale, Leticia ^c   Becquet, Renaud ^a,b   Ekouevi, Didier ^a,b,d   Bosse Amani, Clarisse ^d   Arrivé, Elise ^a,b   Leroy, Valériane ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c African Network for the Care of Children Affected by HIV/AIDS (ANECCA)   (Uganda)

^d Programme national de lutte contre le sida   (Côte d’Ivoire)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; PLACEBO;

AFRICA; ANEMIA; ARTICLE; CAUSE OF DEATH; CHILDHOOD DISEASE; CLINICAL INDICATOR; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALNUTRITION; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 79959788469     PISSN: 07554982     EISSN: 07554982     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.11.021     Document Type: Article

References (53)

1. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report, September 2009. Geneva: WHO, 2009. http://www.who.int/hiv/pub/2009progressreport/en/.
2. UNAIDS, WHO. 2009 AIDS Epidemic update. Geneva: UNAIDS, WHO, 2009. http://data.unaids.org/pub/Report/2009/2009_epidemic_update_en.pdf.
3. Newell M., Coovadia H., Cortina Borja M., Rollins N., Gaillard P., Dabis F. Mortality of infected and uninfected infants born to HIV-infected mother in Africa: a pooled analysis. Lancet 2004, 364:1236-1243.
4. Teglas J., Mayaux M., Blanche S. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA 2000, 284:2871-2872.
5. van Rossum A., Fraaij P., de Grrot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002, 2:93-102.
6. Anglaret X., Chene G., Attia A., Toure S., Lafont S., Combe P., et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999, 353(9163):1463-1468.
7. Laurent C., Diakhaté N., Gueye N.N., Touré M.A., Sow P.S., et al. The senegalese government's highly active antiretroviral therapy initiative. AIDS 2002, 16:1363-1370.
8. Adje-Toure C., Hanson D.L., Talla-Nzussouo N., Borget M.Y., Kouadio L.Y., Tossou O., et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan Cote d'Ivoire. AIDS Res Hum Retroviruses 2008, 24:911-917.
9. Salmi LR. Lecture critique et communication médicale scientifique. Elsevier; 2002.
10. Chintu C., Bhat G.J., Walker A.S., Mulenga V., Sinyinza F., Lishimpi K., et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004, 364:1865-1871.
11. Walker A.S., Mulenga V., Sinyinza F., Lishimpi K., Nunn A., Chintu C., et al. Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial. J Acquir Immune Defic Syndr 2006, 42:637-645.
12. Walker A.S., Mulenga V., Ford D., Kabamba D., Sinyinza F., Kankasa C., et al. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis 2007, 44:1361-1367.
13. Mulenga V., Ford D., Walker A.S., Mwenya D., Mwansa J., Sinyinza F., et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007, 21:77-84.
14. Walker A.S., Ford D., Mulenga V., Thomason M.J., Nunn A., Chintu C., et al. Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children. AIDS Behav 2009, 13:33-41.
15. Laufer M.K., Joep J., van Ooterhout G., Arantza Perez M., Kanyanganlika J. Observational cohort study of HIV-infected African children. Pediatr Infect Dis J 2006, 25:623-627.
16. Harambat J., Fassinou P., Becquet R., Toure P., Rouet F., Dabis F., et al. 18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan. Cote d'Ivoire: a cohort study. BMC Public Health 2008, 8:169.
17. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2008;22:97-105.
18. Ble C., Floridia M., Muhale C., Motto S., Giuliano M., Gabbuti A., et al. Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in Tanzania. Acta Paediatr 2007, 96:1090-1094.
19. Kiboneka A., Wangisi J., Nabiryo C., Tembe J., Kusemererwa S., Olupot-Olupot P., et al. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS 2008, 22:2493-2499.
20. Van Kooten Niekerk NK, Knies MM, Howard J, Rabie H, Zeier M, van Rensburg A, et al. The first 5 years of the family clinic for HIV at Tygerberg Hospital: family demographics, survival of children and early impact of antiretroviral therapy. J Trop Pediatr 2006;52:3-11.
21. Eley B., Davies M.A., Apolles P., Cowburn C., Buys H., Zampoli M., et al. Antiretroviral treatment for children. S Afr Med J 2006, 96:988-993.
22. Bong C.N., Chen S.C., Jong Y.J., Tok T.S., Hsu C.F., Schouten E.J., et al. Outcomes of HIV-infected children with tuberculosis who are started on antiretroviral therapy in Malawi. Int J Tuberc Lung Dis 2007, 11:534-538.
23. Bell F., Bong C.N., Bramson B., Ellis J., Fitzgerald M., Goossens S., et al. Antiretroviral therapy for children in the routine setting in Malawi. Trans R Soc Trop Med Hyg 2007, 101:511-516.
24. Violari A., Cotton M.F., Gibb D.M., Babiker A.G., Steyn J., Madhi S.A., et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359:2233-2244.
25. Bolton-Moore C., Mubiana-Mbewe M., Cantrell R.A., Chintu N., Stringer E.M., Chi B.H., et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007, 298:1888-1899.
26. Jaspan H.B., Berrisford A.E., Boulle A.M. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J 2008, 27:993-998.
27. Reddi A., Leeper S.C., Grobler A.C., Geddes R., France K.H., Dorse G.L., et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal South Africa. BMC Pediatr 2007, 7:13.
28. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2008, 49:523-531. Collaboration KIDS-ART-LINC.
29. van Griensven J, De Naeyer L, Uwera J, Asiimwe A, Gazille C, Reid T. Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care. BMC Pediatr 2008;8:39.
30. O'Brien D.P., Sauvageot D., Olson D., Schaeffer M., Humblet P., Pudjades M. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in ressource-limited settings. Clin Infect Dis 2007, 44:1245-1248.
31. O'Brien D.P., Sauvageot D., Zachariah R., Humblet P. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006, 20(15):1955-1960.
32. Wamalwa D.C., Farquhar C., Obimbo E.M., Selig S., Mbori-Ngacha D.A., Richardson B.A., et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr 2007, 45:311-317.
33. Bong C.N., Yu J.K., Chiang H.C., Huang W.L., Hsieh T.C., Schouten E.J., et al. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi. AIDS 2007, 21:1805-1810.
34. Wamalwa D, Obimbo E, Farquhar C, Mbori-Ngacha D, Inwani I, Wangui A, et al. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya. 5th IAS Conference on HIV Pathogenesis and Treatment; 2009. Abstract: N° MOPEB086.
35. Fatti G, P. Bock, A. Grimwood, S. Wampold, Eley B. Antiretroviral therapy outcomes in rural and urban children attending public health facilities in South Africa. 5th IAS Conference on HIV Pathogenesis and Treatment 2009. Abstract no MOPEB077.
36. Bock P., Boulle A., White C., Osler M., Eley B. Provision of antiretroviral therapy to children within the public sector of South Africa. Trans R Soc Trop Med Hyg 2008, 102:905-911.
37. Fassinou P., Elenga N., Rouet F., Laguide R., Kouakoussui K.A., Timite M., et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan. Cote d'Ivoire. AIDS 2004, 18:1905-1913.
38. Marazzi M.C., Germano P., Liotta G., Buonomo E., Guidotti G., Palombi L. Pediatric highly active antiretroviral therapy in Mozambique: an integrated model of care. Minerva Pediatr 2006, 58:483-490.
39. De Beaudrap P, Rouet F, Fassinou P, Kouakoussui A, Mercier S, Ecochard R, et al. CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2008;49:70-6.
40. Boulle A., Bock P., Osler M., Cohen K., Channing L., Hilderbrand K., et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008, 86:678-687.
41. Nyandiko W.M., Ayaya S., Nabakwe E., Tenge C., Sidle J.E., Yiannoutsos C.T., et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defic Syndr 2006, 43:418-425.
42. Rouet F., Fassinou P., Inwoley A., Anaky M.F., Kouakoussui A., Rouzioux C., et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 2006, 20:2315-2319.
43. Prendergast A., Mphatswe W., Tudor-Williams G., Rakgotho M., Pillay V., Thobakgale C., et al. Early virological supression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 2008, 22:1333-1343.
44. UNAIDS. Use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Recommendations and operational issues. Geneva: UNAIDS; 2000. http://www.unaids.org/whatsnew/press/eng/recosummary.doc.
45. Gibb D., Newberry A., Klein N., de Rossi A., Babiker A. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet 2000, 355:1331-1332.
46. Ciaranello A.L., Chang Y., Margulis A., Bernstein A., Bassett I., Losina E., et al. Effectiveness of pediatric combination antiretroviral therapy (ART) in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis 2009, 49:1915-1927.
47. Ellis J., Molyneux E.M. Experience of anti-retroviral treatment for HIV-infected children in Malawi: the 1st 12 months. Ann Trop Paediatr 2007, 27:261-267.
48. Kekitiinwa A., Lee K.J., Walker A.S., Maganda A., Doerholt K., Kitaka S.B., et al. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr 2008, 49:384-392.
49. Carter RJ, Katyal M, Toro P, Abrams EJ. Immunologic response and survival of infants initiating antiretroviral treatment (ART) at less than one year of age compared to older children enrolled at MTCT-Plus Initiative sites in 8 African countries and Thailand. 5th IAS Conference on HIV Pathogenesis and Treatment, 2009;. Abstract: no MOPEB048.
50. Colvin C, J, Knight L, Van Cutsem G, Abrahams M, Coetzee D, Goemaere E, et al. Paediatric outcomes after five years on ART in Khayelitsha Township, South Africa. 5th IAS Conference on HIV Pathogenesis and Treatment; 2009;. Abstract: no CDB109.
51. Moultrie H, Yotebieng M, Kuhn L, Meyers T. Mortality and Virological Outcomes of 2105 HIV-infected Children Receiving ART in Soweto, South Africa. 16th Conference on Retroviruses and Opportunistic Infections: 2009; Abstract: no 97.
52. Smit EJ, Rabie H, Prozesky HMC. Pediatric outcome 42 months after highly active antiretroviral therapy availability in the public sector - the Tygerberg Children's Hospital experience. 5th IAS Conference on HIV Pathogenesis and Treatment; 2009; Abstract: no MOPEB079.
53. Tanoh F, H Signaté Sy, F Dicko, K Malateste, L Renner, K Peterson, et al. 12-month mortality, loss-to-program, and immunological response in ART-treated children. The International Epidemiologic Databases to Evaluate AIDS, Pediatric West African Database, 2000 to 2007. 16th Conference on Retroviruses and Opportunistic Infections: 2009; abstract:no 876 2009.